Navigation Links
Omeros Announces Publication of Data From Antifibrinolytic Program
Date:2/10/2011

PI-2, referred to as KD1, inhibits plasmin but, like Trasylol®, also inhibits kallikrein and Factor XIa. Dr. Bajaj and her colleagues demonstrate that a minimal change to the sequence of the KD1 protein increases its activity against plasmin approximately 6-fold while dramatically reducing its inhibition of kallikrein and Factor XIa by more than 100-fold. Because the variant KD1 proteins developed by the authors and exclusively licensed to Omeros are more selective than Trasylol®, they could provide more effective bleeding control with fewer side effects. Additionally, as a human protein derivative, these agents are expected to reduce the potential for immunological side effects.

The paper shows the variant KD1 reduced blood loss in a rodent model of surgical bleeding by 85 percent relative to saline treatment, demonstrating an antifibrinolytic effect at least equal to Trasylol®. Similar antifibrinolytic activity of a related variant KD1 also controlled by Omeros was confirmed by other researchers using human plasma evaluated by thromboelastography. Thromboelastograms are used clinically to assess the level of fibrinolysis in patients during surgical procedures at risk for extensive blood loss.

Importantly, the authors also found that the variant KD1 does not slow blood clotting as measured by the partial thromboplastin time (aPTT), a standard indicator of blood's ability to coagulate.  Conversely, Trasylol® increased aPTT by 60 percent, which could significantly prolong bleeding in trauma and surgical patients.  

Omeros believes the efficacy and improved selectivity of the variant KD1 provides a novel approach to the control of bleeding from surgery and trauma. Omeros has initiated scale-up activities of its lead antifibrinolytic compound in preparation for clinical trials.  

About Omeros' Antifibrinolytic Program

Omeros is developing a series of novel antifibrinolytic agents for the cont
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Licenses Novel Antifibrinolytic Agents
2. Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
3. Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
4. Omeros to Present at the BioCentury NewsMakers Conference
5. Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
6. Omeros Successfully Unlocks Orphan GPCRs
7. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
8. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
9. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
10. Daniel K. Spiegelman Elected to Board of Directors of Omeros
11. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... DUBLIN , Dec. 24, 2014  Actavis ... that the Company has received a complete response ... (FDA) for its New Drug Application (NDA) for ... for the treatment of hypertension.   Photo ... we are disappointed in the receipt of a ...
(Date:12/24/2014)... N.J. , Dec. 24, 2014 ... a late-stage biopharmaceutical company developing products that address ... oncology and biodefense, announced today that on December ... public offering. The Company raised approximately ... and intends to use the net proceeds from ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, ... PTN), a biopharmaceutical company developing targeted, receptor-specific peptide ... unmet medical need and commercial potential, today announced ... of 2,050,000 shares of its common stock and ... its common stock.  Funds under the management of ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... MASPETH N.Y., May 1, 2012 /PRNewswire-iReach/ ... global expedited transportation, logistics, and warehouse fulfillment services, ... Tom Brennan as Vice President Strategic Accounts & ... be responsible for implementing and accelerating critical strategic ...
... MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced that ... 2012: Deutsche Bank 37th Annual Healthcare Conference Tuesday, May ... America Merrill Lynch 2012 Healthcare Conference Tuesday, May 15, at 3:40 ... each event will be available on the Investor Relations section of ...
Cached Medicine Technology:Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences 2Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences 3
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, ... illnesses can receive effective, less expensive care from a clinic ... a team of dedicated health care professionals, a new study ... and need either hospitalization or a trip to the emergency ... clinic at the University of Texas in Houston versus usual ...
(Date:12/25/2014)... THURSDAY, Dec. 25, 2014 (HealthDay News) -- Overeating is common ... you eat in moderation, an expert says. "Don,t arrive ... up calories if you know you,ll be attending a party, ... Jill Ashbey-Pejoves, lead dietitian at Northern Westchester Hospital in Mount ... better to eat healthy during the day and even to ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 ... "fountain of youth" drug that can delay the effects of ... study suggests. Seniors received a significant boost to their ... signaling pathway linked to aging and immune function, researchers with ... medication, a version of the drug rapamycin, improved the seniors, ...
(Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... ) continue to move forward in a number of ... District of West Virginia, Bernstein Liebhard LLP reports. According ... Court is scheduled to convene a Joint Status Conference ... at 10:00 a.m. Parties have been directed to submit ...
(Date:12/25/2014)... Plugin creators from Pixel Film Studios ... customizable business presentation tool made specifically for Final ... business tool, users can now display their stats and ... Film Studios. “ProFire 5k gives users a multiple options ... to a presentation” , Pixel Film Studios takes the ...
Breaking Medicine News(10 mins):Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... Association of Canada states that learning disabilities diagnosed ... on people. Depression, anxiety, suicidal thoughts and unemployment ... with such disabilities. ,Philippa Slater, B.C. ... finding and says that many such people resort ...
... Danish study shows that if you happen to posses a ... ,The gene in question is a specific ... associated with increased iron accumulation, which affects how the body ... Without treatment, the condition causes liver enlargement ...
... of tiny babies born in UK is increasing. The researchers ... weighing less than 2.5kg in 2006. In 1989, it was ... has also urged the government to provide more financial support ... care for all newborns in intensive care. According to the ...
... with cacao liquor proanthocyanidins (CLPr) reduced blood glucose ... human diabetics// significant benefits, says a new study ... can dose-dependently prevent the development of hyperglycaemia in ... in the journal Nutrition. "The dietary intake of ...
... joint HIV surveillance and prevention efforts, which they began in ... governments reported record numbers of HIV cases in 2006, China ... Hong Kong Department of Health reported 373 new HIV cases ... in 2005. Guangdong reported 4,823 new HIV cases from January ...
... with terms like ‘grumpy old man’, ‘old fogies’ and other such, ... it’s older people who are more optimistic about life. ... older, and it is the young who tend to have a ... of a survey of 150 persons, the subjects of varied ages ...
Cached Medicine News:Health News:Gene Mutation Linked With Risks of Stroke 2Health News:Cocoa Polyphenols may Offer Diabetes Benefits - Study 2Health News:Hong Kong, Guangdong Province To Increase Joint HIV/AIDS Surveillance 2
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
The upper body blanket covers the upper torso, arms, neck, and head of the patient....
The Electri-Cool® II is the premier choice when it comes to localized cold therapy systems. system offers the widest variety of application-specific pads and wraps, for your convenience....
Complete Cataract Competence , OPMI VISU 140 is compact, good and economical. It's everything a cataract specialist needs today....
Medicine Products: